ALK and lung carcinoma: First, we tested the growth inhibitory properties of crizotinib on a series of lung cancer cells lines including SPC-A1, HCC827, H1975 and A549, and found that although none of these cell lines harbors an EML4-ALK fusion protein, most of them were responsive to crizotinib treatment (Figure 1A).